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Background: IL-35 was recently identiﬁed as an anti-inﬂammatory cytokine. We previously reported that
recombinant fusion protein of murine IL-35 and human IgG1 Fc fragment (rIL-35) reduced Th2 cytokines
(IL-4 and IL-5) in vitro. However, it is unclear whether IL-35 can attenuate nasal allergic responses and
symptoms of allergic rhinitis in vivo.
Methods: To investigate the in vivo effect of IL-35 on allergic rhinitis in mice, mice were sensitized with
ovalbumin (OVA). Intranasal administration of rIL-35 and intranasal challenge of OVA were then per-
formed. Nasal symptoms were estimated after the last nasal challenge. Nasal tissue and cervical lymph
nodes (CLN) were collected. OVA-speciﬁc IgE in sera, OVA-speciﬁc T cell response, and the production of
cytokines (IL-4, IL-5, and IL-10) stimulated by the OVA antigen were measured. The transcription level of
Foxp3 and the frequency of CD4þCD25þ regulatory T cells were also measured.
Results: rIL-35 signiﬁcantly inhibited the number of sneezes and nasal rubbing movements. It also
reduced the number of eosinophils in the nasal mucosa and signiﬁcantly decreased the level of OVA-
speciﬁc IgE, the OVA-speciﬁc T cell proliferation, and the production of IL-4 and IL-5. Furthermore, rIL-
35 signiﬁcantly increased the production of IL-10, the transcription level of Foxp3, and the frequency
of CD4þCD25þ regulatory T cells.
Conclusions: This study showed for the ﬁrst time that rIL-35 inhibits nasal allergic responses and
symptoms in mice, and that rIL-35 increases IL-10, Foxp3, and CD4þCD25þ regulatory T cells in CLN. This
study also suggests that intranasal administration of IL-35 can attenuate allergic rhinitis.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Regulatory T cells (Tregs) play an important role in inhibition of
immune response. Regulatory T cells mediate maternal tolerance to
the fetus.1 CD4þCD25þ regulatory T cells also inhibit antigen-
speciﬁc T cell response,2,3 and can reverse chronic allergen-
induced inﬂammation and prevent airway remodeling.4
IL-35, a heterodimeric hematopoietin of EpsteineBarr virus-
induced gene 3 (EBI3) and the p35 subunit of IL-12, was identi-
ﬁed as an anti-inﬂammatory and immuno-suppressive cytokine in
2007.5 IL-35 is also an IL-12 family cytokine, and is reported to be
produced mainly by Tregs.5
IL-35 protein and mRNA levels in allergic asthmatics were
shown to be lower than in healthy controls.6 The frequencies ofolaryngology, Nagoya City
oya, Aichi 467-8601, Japan.
. Suzuki).
ety of Allergology.
rgology. Production and hosting by Else
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016), http://dx.doi.org/10.101CD4þCD25þ Foxp3þ Tregs and CD4þ IL-12p35þ T cells in allergic
asthma patients were also found to be decreased.6 Whitehead et al.
showed that the production of IL-17, allergic airway hyper-
responsiveness, and the numbers of macrophages, neutrophils,
lymphocytes, and eosinophils in bronchoalveolar lavage ﬂuid
(BALF) increased in mice deﬁcient in Ebi-3, one of the IL-35 sub-
units.7 Recently IL-35 has been reported to have an effect on BALF
has been reported.8e10 Huang et al.8 showed that IL-4, IL-5, and IL-
13 in BALF were inhibited by administration of plasmid DNA
encoding recombinant single-chain IL-35. Dong et al.9 also reported
that administration of recombinant fusion protein of murine IL-35
and human Fc fragment (rIL-35) reduced eosinophil counts in BALF.
Li et al.10 documented a reduction in the numbers of inﬂammatory
cells and levels of IL-4, IL-5, IL-13, and IL-17 in BALF with admin-
istration of adenovirus expressing IL-35. These ﬁndings suggest
that IL-35 can attenuate asthma. However, reports of IL-35 in
relation to allergic rhinitis are very limited.
Many people around the world suffer from allergic rhinitis.
While intranasal administration of corticosteroids is a useful ther-
apy for the control of allergic rhinitis, it is possible that IL-35may bevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
tion of IL-35 inhibits allergic responses and symptoms in mice with
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agement of allergic rhinitis is not yet certain.
We previously reported that recombinant fusion protein of
murine IL-35 and human IgG1 Fc fragment (rIL-35) reduced Th2
cytokines (IL-4 and IL-5), IL-17, and TNF-alfa generated by co-
culture of splenic dendritic cells and CD4þCD25 T cells of an
allergic rhinitis model mouse in vitro,11 and that rIL-35 increased
IL-10 in vitro.11 However, to our knowledge there has been no prior
study examining the in vivo effect of IL-35 on allergic symptoms
and allergic rhinitis. In this study, therefore, we examined the effect
of intranasal administration of rIL-35 on allergic symptoms and
allergic rhinitis.Methods
Immunization and treatment
Eight week-old male BALB/c mice, which were purchased from
Japan SLC, Inc. (Shizuoka, Japan), were sensitized with ovalbumin
(OVA, grade V, SigmaeAldrich, St. Louis, MO, USA) and 2 mg Al
(OH)3 intraperitoneally twice on days 0 and 14. These mice were
also challenged intranasally (i.n.) on days 21 through 27 with OVA
(200 mg). Intranasal administration (40 ml saline) of 0.1 mg recom-
binant fusion protein of murine IL-35 and human IgG1 Fc fragment
(rIL-35, Chimerigen Laboratories, San Diego, CA) was performed an
hour before OVA intranasal challenge on days 21 through 27. In a
preliminary experiment with administration of 0.01 mg and 0.1 mg
of rIL-35, we determined that 0.1 mg was more suitable, because
there were bigger differences between the rIL-35 group and the
control groups in the experiment with 0.1 mg (data not shown). In
the control groups, intranasal administration (40 ml saline) of re-
combinant human IgG1 Fc fragment (rFc, AdipoGen, San Diego, CA,
USA) only (0.1 mg, rFc control group) or PBS only (PBS control group)
was performed an hour before OVA intranasal challenge on days 21
through 27. A schematic protocol of immunization and treatment is
shown in Figure 1. rIL-35 and rFc were both produced in the same
cells, CHO cells. Nasal tissue and cervical lymph nodes (CLN) were
collected on day 28. Mice were housed in an environmentally-
controlled animal facility at Nagoya City University in Japan. TheIntraperitoneal injection 
of OVA and Al(OH)3
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Fig. 1. Schematic protocol of experiment. Intranasal administration of PBS alone (PBS),
recombinant human IgG1 Fc fragment alone (rFc), or recombinant fusion protein of
murine IL-35 and human IgG1 Fc fragment (rIL-35) was performed one hour before
OVA intranasal challenge.
Please cite this article in press as: Suzuki M, et al., Intranasal administra
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Animals of Nagoya City University. Every effort was made to
minimize the discomfort of the animals.
Nasal allergic symptoms
Immediately after the last nasal challenge on day 27, the number
of sneezes and nasal rubbing movements was counted for 20 min
according to the method previously reported.2
OVA-speciﬁc T cell response
Lymphoid cells (2  106 cells/ml) from CLN were cultured with
the OVA antigen (100 mg/ml) for 72 h at 37 C in RPMI-1640 me-
dium (Sigma, St Louis, MO, USA) containing 10% FBS, penicillin G/
streptomycin (Sigma). Cells were pulsed with 1 mCi of [3H] thymi-
dine (Perkin Elmer, Billerica, MA, USA) for the last 16 h of culture.
Culture volume per each well was 150 ml. Cells were harvested onto
glass ﬁber ﬁlters, and incorporated radioactivity was quantitated
using a liquid scintillation counter. Results were expressed as cpm.
Measurement of OVA-speciﬁc IgE and IgG1
Mouse serum titers of OVA-speciﬁc IgE were measured by
ELISA in accordance with the method previously reported.2,3,11
ELISA 96-well plates were incubated and coated with 100 ml
anti-mouse IgE monoclonal antibody (Yamasa, Tokyo, Japan,
Clone No. 6HD5, 1 mg/ml diluted by coating buffer which includes
1.59 g Na2CO3 and 2.93 g Na2CO3 in 500 ml) overnight at 4 C.
Non-speciﬁc binding was blocked by incubation with 200 ml PBS
including 5% bovine serum albumin (BSA) at room temperature
for 4 h. After washing with wash buffer (PBS containing 0.05%
Tween® 20) 3 times, sera (100 ml) at a dilution of 1/5 with PBS
were added to the plate, and incubated at 37 C for 2 h. After
washing with wash buffer 3 times, 100 ml biotinylated OVA was
added to the well and incubated at 37 C for an hour. The plates
were then incubated with 100 ml avidin-peroxidase at 37 C for
an hour after washing 3 times. The TMB microwell peroxidase
substrate system (KPL, Gaitherburg, MD, USA), which develops a
deep blue color when reacted with peroxidase conjugates in
ELISA, was applied according to the manufacturer's instructions
after washing 6 times. Optical density (O.D.) was measured at
450 nm. OVA-speciﬁc IgG1 was also measured by ELISA. ELISA
96-well plates were incubated and coated with 100 ml OVA
(10 mg/ml) diluted by coating buffer overnight at 4 C. Nonspe-
ciﬁc binding was blocked by incubation with 200 ml PBS
including 5% BSA at room temperature for 4 h. After washing 3
times, 100 ml serum samples at a dilution of 1/20 with PBS were
added to the plates and incubated at 37 C for 2 h. HRP-labeled
anti-mouse IgG1 (Bio-Rad, San-Diego, CA, USA, 100 ml) at a
dilution of 1/200 with PBS was added and incubated at 37 C for
an hour. After washing 6 times, the same substrate was applied,
and O.D. was measured as described.
Measurement of in vitro cytokine release from CLN
Lymphoid cells (2  106 cells/ml) from CLN were cultured with
OVA (100 mg/ml) for 72 h at 37 C. After this incubation, the cell-free
culture supernatants were collected. Quantities of cytokines (IL-4,
IL-5, and IL-10) in the culture supernatants were measured using a
sandwich ELISA. Plates were coated with anti-mouse IL-4, IL-5, or
IL-10 (PeproTech, Rocky Hill, NJ, USA). The culture supernatant was
also added, after which plates were incubated with the second







































































Fig. 2. Intranasal administration of rIL-35 inhibited nasal sneezes, nasal rubbing
movements, and nasal eosinophilia. Mice received PBS alone (PBS); recombinant hu-
man IgG1 Fc fragment alone (rFc); or recombinant fusion protein of murine IL-35 and
human IgG1 Fc fragment (rIL-35). The number of nasal sneezes (A) and nasal rubbing
movements (B) was counted for 20 min immediately after the last nasal challenge. The
number of eosinophils inﬁltrated into the nasal mucosa of the nasal septum was also
measured microscopically in a ﬁeld of view at 400 magniﬁcation (C). Data are indi-
cated as mean ± SD of ﬁve mice per group. Data are representative of two independent
experiments with similar results. **P < 0.01 by ANOVA.
M. Suzuki et al. / Allergology International xxx (2016) 1e6 3Standard curves were made by recombinant cytokines. The detec-
tion limits of these cytokines were 10e20 pg/ml.
Real time PCR
Total RNA was isolated from CLN using Trizol (Thermo Fisher
Scientiﬁc, Yokohama, Japan) according to the manufacturer's pro-
tocol. In brief, 20 mg RNA was digested by DNase I, extracted with
phenol:chloroform (3:1), precipitated with ethanol, washed with
ethanol, and dissolved in RNAse-free water. The ﬁrst-strand cDNA
was generated with the SuperScript Preampliﬁcation System
(Thermo Fisher Scientiﬁc).
Real-time polymerase chain reaction (PCR) was performed by
SYBR Green PCR Master mix (Stratagene, La Jolla, CA, USA) and
gene-speciﬁc primers. The PCR reaction conditions were performed
for 40 cycles. Mouse GAPDH mRNA was used for normalization to
ensure equal amounts of starting RNA.
The primers used in this study were:
Fox p 3, sense 50-CAGCTGCCTACAGTGCCCCTAG-30 and antisense
50-CATTTGCCAGCAGTGGGTAG CTG-30; GAPDH, sense 50-TGATGA-
CATCAAGAAGGTGGTGAA-30 and antisense 50-TCCTTGGAGGCCAT
GTAGGCCAT-30.
Flow cytometry
A phenotypic analysis of T cells was performed on a FACScan, as
previously described.12 T cells were harvested and stained with
CYChrome-conjugated anti-mouse CD4 and PE-conjugated anti-
mouse CD25 monoclonal antibody (eBioscience, San Diego, CA,
USA).
Pathology
The heads were decalciﬁed and sectioned. Three micrometer
thick sections of nasal tissue were stained with Luna staining. The
number of eosinophils in the nasal mucosa of the nasal septumwas
counted microscopically in a ﬁeld of view at 400 magniﬁcation.
The number of eosinophils in six different randomly selected places
in the anterior, middle, and posterior areas on the right side and left
sides was counted each mouse. Six results was averaged each
mouse, and the mean ± SD of 5 mice was calculated. The observer
counted the number of eosinophils blinded to treatment.
Statistics
Means and standard deviations were calculated for each group
of mice and data were statistically analyzed using one-way ANOVA
followed by the NewmaneKeuls Test. P < 0.05 was considered
statistically signiﬁcant.
Results
Reduction in the number of nasal sneezes, rubbing movements, and
eosinophilia in nasal mucosa
In order to evaluate the effect of rIL-35 on nasal allergic symp-
toms, the number of nasal sneezes and rubbing movements were
counted immediately after the last nasal challenge on day 27.
Intranasal administration of rIL-35 signiﬁcantly reduced the num-
ber of nasal sneezes (Fig. 2A) and nasal rubbing movements
(Fig. 2B). Next, the number of eosinophils in nasal mucosa was
counted to examine the effect of rIL-35 on eosinophilia. The num-
ber of eosinophils in mice treated by rIL-35 was signiﬁcantly lower
than that in control mice receiving rFc IgG alone (rFc control mice)
or PBS alone (PBS control mice) (Fig. 2C).Please cite this article in press as: Suzuki M, et al., Intranasal administra
allergic rhinitis, Allergology International (2016), http://dx.doi.org/10.101Inhibition of OVA-speciﬁc T cell response of cervical lymph nodes
(CLN) by rIL-35
To examine the capacity of rIL-35 to affect the T cell response,
which is associated with an allergic response, we measured the
OVA-speciﬁc T cell response in CLN. The OVA-speciﬁc T cell
response in mice that received rIL-35 was signiﬁcantly lower than
that in the rFc or PBS control mice (Fig. 3).
Inhibition of OVA-speciﬁc IgE and IgG1
In order to investigate the effect of rIL-35 on IgE and IgG1, we
measured OVA-speciﬁc IgE and IgG1 in sera. The level of OVA-
speciﬁc IgE in mice receiving rIL-35 was signiﬁcantly lower than
that in the rFc or PBS control mice (Fig. 4A). And rIL-35 signiﬁcantly















































Fig. 3. The effects of rIL-35 on OVA-speciﬁc T cell response. Mice received PBS alone
(PBS); recombinant human IgG1 Fc fragment alone (rFc); or recombinant fusion pro-
tein of murine IL-35 and human IgG1 Fc fragment (rIL-35). Lymphoid cells were
collected from CLN, and OVA-speciﬁc T cell response was measured. Data are indicated
as mean ± SD of ﬁve mice per group. Data are representative of two independent
experiments with similar results. **P < 0.01 versus counterpart group by ANOVA.
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To investigate the effect of rIL-35 on IL-4, IL-5, and IL-10 cyto-
kines, we measured the level of IL-4, IL-5, and IL-10 cytokines
cultured with OVA antigen. rIL-35 signiﬁcantly reduced the pro-
duction of IL-4 and IL-5 (Fig. 5A, B). rIL-35 was also found to








Effect of rIL-35 on Foxp3 transcript levels and the frequency of
CD4þCD25þ T cells
Next, we examined the effect of rIL-35 on Foxp3 transcript levels







































Fig. 4. Intranasal administration of rIL-35 inhibited OVA-speciﬁc IgE and IgG1. Intra-
nasal administration of PBS alone (PBS); recombinant human IgG1 Fc fragment alone
(rFc); or recombinant fusion protein of murine IL-35 and human IgG1 Fc fragment (rIL-
35) was performed. Sera were collected, and OVA-speciﬁc IgE (A) and IgG1 (B) in sera
were measured using ELISA. Data are indicated as mean ± SD of ﬁve mice per group.
Data are representative of two independent experiments with similar results.
**P < 0.01 versus counterpart group by ANOVA.
rFc rIL-35PBS
0
Fig. 5. The effect of intranasal administration of rIL-35 on production of IL-4, IL-5, and
IL-10 in CLN. Intranasal administration of PBS alone (PBS); recombinant human IgG1 Fc
fragment alone (rFc); or recombinant fusion protein of murine IL-35 and human IgG1
Fc fragment (rIL-35) was performed. Lymphoid cells were collected from CLN, and cells
were cultured with OVA antigen. IL-4 (A), IL-5 (B), and IL-10 (C) in the supernatant
were measured by ELISA. Data are indicated as mean ± SD of ﬁve mice per group. Data
are representative of two independent experiments with similar results. **P < 0.01
versus counterpart group by ANOVA.
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allergic rhinitis, Allergology International (2016), http://dx.doi.org/10.101whether rIL-35 can induce regulatory T cells. Transcript levels of
Foxp3 were detected at the mRNA level with real time PCR. It was
shown that rIL-35 signiﬁcantly increased transcript levels of Foxp3
(Fig. 6A). Next, we examined the expression of CD4þCD25þ Tcells in
CLN. Flow cytometric analysis revealed that the percentage of
CD4þCD25þ regulatory T cells in mice receiving rIL-35 was signif-
icantly higher than that in the rFc or PBS control mice (Fig. 6B).Discussion
It has been suggested that EBI3 is an important immunomod-
ulator in the fetus.13 Production of IL-35 by Tregs increases
following contact with conventional T cells
(CD4þCD25CD45RBhigh T cells).14 Treatment of naïve T cells with
IL-35 generates regulatory T cells that induce inhibition through IL-
35 but not through other inhibitory cytokines such as IL-10 and
transforming growth factor-b (TGF-b).15 rIL-35 has therapeutic ef-
fects against collagen-induced arthritis through the expansion of
regulatory T cells and suppression of Th17 cells.16 Therefore, IL-35















































Fig. 6. The effect of rIL-35 on Foxp3 gene expression and the frequency of CD4þCD25þ
T cells in CLN. Mice received PBS alone (PBS); recombinant human IgG1 Fc fragment
alone (rFc); or recombinant fusion protein of murine IL-35 and human IgG1 Fc frag-
ment (rIL-35). Real time PCR analysis of Foxp3 (A) and ﬂow cytometric analysis of
CD4þCD25þ T cells (B) are shown. Data are indicated as mean ± SD of ﬁve mice per
group. Data are representative of two independent experiments with similar results.
**P < 0.01 versus counterpart group by ANOVA.
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reduced the number of sneezes and nasal rubbing movements,
suggesting that IL-35 is effective in controlling allergic rhinitis
symptoms in mice. Eosinophilia in nasal mucosa was also reduced
by rIL-35 in this study. IL-35 may therefore inhibit nasal allergic
symptoms through reduction in the number of eosinophils in the
nasal mucosa.
Huang et al.8 showed that IL-4, IL-5, and IL-13 in bron-
choalveolar lavage ﬂuid (BALF) were inhibited by intratracheal
instillation of vector expressing IL-35, and that intramuscular in-
jection of vector expressing IL-35 inhibited the IgE level. Dong
et al.9 showed that intraperitoneal injection of rIL-35 reduced
eosinophil counts in BALF. Li et al.10 showed that intranasal
administration of adenovirus expressing IL-35 reduced the
numbers of inﬂammatory cells and levels of IL-4, IL-5, IL-13, and IL-
17 in BALF. These ﬁndings suggest that intratracheal, intramuscular,
intraperitoneal, or intranasal administration of IL-35may attenuate
asthma. However, it had been unclear whether administration of
IL-35 could inhibit allergic symptoms. This study suggests that
intranasal administration of IL-35 may in fact inhibit allergic
symptoms from allergic rhinitis.
We examined CLN because CLN are the regional lymph nodes of
the upper airway. Nasal sensitizationwith antigen induced Th2 cell
accumulation and B cells to become IgE-producing plasma cells in
CLN.17 This study showed that rIL-35 reduced antigen-speciﬁc T cell
responses and production of IL-4 and IL-5 in CLN. Aberrant
expansion of T cells producing type 2 cytokines, such as IL-4 and IL-
5, induces allergic rhinitis.18 CD4þ T cells induce IgE production and
sensitization of allergy through IL-4.19 They also induce activation
and migration of eosinophils, and induce allergic symptoms
through IL-5.20 Considering this, intranasal administration of IL-35Please cite this article in press as: Suzuki M, et al., Intranasal administra
allergic rhinitis, Allergology International (2016), http://dx.doi.org/10.101may attenuate allergic rhinitis through decrease of IL-4 and IL-5 in
CLN.
Intranasal administration of IL-10 can inhibit antigen-induced
airway hyper-responsiveness and reduce the number of eosino-
phils and neutrophils in BALF.21 Baumann et al. showed the possi-
bility that IL-10 can inhibit nasal mucosal allergy.22 Therefore, we
measured the production of IL-10 production in this study, and
found that intranasal administration of rIL-35 increased IL-10
production in CLN. Although IL-35 can facilitate the trans-
formation from CD4þ effector T cells to Treg cells,15 IL-10 can pro-
mote survival of CD4þFoxp3þ Treg directly in vivo.23 Considering
this, IL-10 induced by IL-35 may play an important role in vivo. IL-
35 might have an effect not only on facilitation of Treg but also on
Treg survival through IL-10 production.
Induction of Foxp3 expression can induce Tregs extrathymically
from CD4þCD25 naïve T cells.24 Foxp3 is considered to be a
regulator of Tregs. In this study, we showed that intranasal
administration of rIL-35 increased Foxp3 gene expression and the
frequency of CD4þCD25þ T cells, which are regulatory T cells, in
CLN. Yamada et al.25 also suggested that Tregs in CLN are involved in
the inhibition of allergic rhinitis in mice receiving sublingual
immunotherapy (SLIT), and SLIT has been shown to be clinically
effective in patients with allergic rhinitis.26 Considering this, the
effect of intranasal therapy with IL-35 may be due to a mechanism
close to that of SLIT, and this therapy may modulate the upper
stream of allergic responses.
Collison et al. reported that iTr35, which is Treg induced by IL-
35, does not express or require Foxp3.15 In this study, however,
intranasal administration of rIL-35 enhanced Foxp3 gene expres-
sion of CLN. IL-10 can maintain and enhance Foxp3 gene expres-
sion,23,27 although intranasal administration of rIL-35 increased IL-
10 production in CLN. We also previously reported that rIL-35
enhanced IL-2 production in vitro. IL-2 is essential for induction
of Foxp3þ regulatory T cells by TGF-beta, and can induce expansion
of Foxp3þ regulatory T cells.28,29 Furthermore, IL-2 receptor beta-
dependent STAT5 activation is required for the development of
Foxp3þ regulatory T cells.30 The mechanism of immune response is
complex in vivo. Considering the above, IL-35 may enhance Foxp3
gene expression through an increase the production of IL-2 and IL-
10 indirectly, but not directly.
Little information is available about the effect of Tregs on airway
infection. However, Haeryfar et al. showed that Treg depletion
signiﬁcantly augmented CD8þ T cell responses, IFN-gamma pro-
duction, and cytolytic activity in response to inﬂuenza virus.31
Boettler et al. also reported that Treg suppressed inﬂuenza virus-
speciﬁc CD8þ T cell proliferation.32 Considering this, there is a
risk that intranasal administration of IL-35 increases airway infec-
tion through facilitation of Tregs. In contrast, Terrada showed that
injection of inﬂuenza virus hemagglutinin (HA)-speciﬁc Treg
controlled uveoretinitis, and deletion of Tregs exacerbated clinical
signs of uveoretinitis.33 Induced Tregs in coronaviral infection also
protects against greater severity of the disease.34 Anghelina et al.35
showed that Tregs depletion resulted in increased mortality in
coronavirus-induced acute encephalitis, and transfer of Tregs
increased survival from 0% to 50%. At the moment, the association
between Tregs and airway infection is unclear. The effect of Tregs
on airway infections may vary depending on the situations. To
elucidate the association between Tregs and airway infections,
further studies are needed.
This novel intranasal therapy with rIL-35 is an antigen-
independent therapy. Many patients with allergic rhinitis have
sensitization to multiple antigens, and it is often difﬁcult for phy-
sicians to identify the speciﬁc causative antigen in patients with
allergic rhinitis. In the light of these observations, it is crucial totion of IL-35 inhibits allergic responses and symptoms in mice with
6/j.alit.2016.08.014
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novel therapies for allergic rhinitis.
In this study, we showed that intranasal administration of rIL-35
inhibited nasal allergic symptoms, eosinophilia in the nasal mu-
cosa, and production of IL-4 and IL-5 in CLN, suggesting that this
therapy can alleviate allergic rhinitis. This therapy also increased
the production of IL-10, gene expression of Foxp3, and frequency of
CD4þCD25þ T cells in CLN, suggesting that it can facilitate Tregs.
These ﬁndings should contribute to the development of a new
therapeutic approach to allergic rhinitis. Further study is warranted
to develop this strategy.
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